Oguzcan Kınıkoglu

30PUBLICATIONS
139CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsInnate immunityHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Sep 26, 2026
FOLFOX Plus Bevacizumab Rechallenge Versus Regorafenib as Third-Line Treatment in Metastatic Colorectal Cancer: The Role of the Oxaliplatin-Free Interval.

|Jul 28, 2026
Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.

|Apr 14, 2026
Clinicopathologic Determinants of Overall Survival in Adrenocortical Carcinoma: A SEER-Based Population Study.

Anıl Yıldız, Oguzcan Kınıkoğlu

|Mar 28, 2026
Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCR.

Ayberk Bayramgil, Mehmet Haluk Yücel, Ezgi Turkoglu

|Mar 14, 2026
Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk-Stratified Analysis.

Sila Oksuz, Oguzcan Kinikoglu, Ugur Ozkerim

|Feb 11, 2026
Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Salih Tunbekici, Hamit Bal, Oguzcan Kınıkoglu

Pageof 5

Frequent Collaborators

23 joint publications

Deniz Işık

23 joint publications

Hatice Odabas

21 joint publications

Nedim Turan

19 joint publications

Heves Surmeli